drugset / Trial / NCT03088345

Early Use of Vasopressin in Post-Fontan Management

NCT03088345

Phase 2/3 Completed 20 enrolled Medical College of Wisconsin
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This is an investigator initiated, prospective, single-center, double-blinded, randomized, placebo-controlled trial of post-operative low dose vasopressin infusions as an early treatment of low systemic perfusion in pediatric patients following Fontan palliation.

Timeline

Start
2017-03-06
Primary completion
2018-11-01
Completion
2019-01-28

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Vasopressin Peptide 0.0003 iu/kg